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Abstract
The role of human papillomavirus and other risk factors in 
malignant and premalignant skin complications following 
heart, heart-lung and lung transplantation.
Simal Soin
Addenbrooke's Hospital, Cambridge.
A side-effect of immunosuppression following renal transplantation 
is the development of skin infections and non-melanoma skin 
cancers which are associated with human papillomavirus (HPV) 
infection and sun exposure. Heart-lung transplant recipients are on 
average younger than renal allograft recipients and also receive a 
higher level of immunosuppressive therapy. To ascertain the 
incidence of HPV-associated cutaneous complications after heart 
and lung transplantation and the role of potential risk factors, we 
have investigated 397 of the surviving transplant recipients by 
means of questionnaire, review of medical records, and a proportion 
by interview and examination.
A high incidence of warts and non-melanoma skin cancers 
was found in heart-lung and heart transplant population studied in 
accordance with previous studies on renal transplant recipients. 
These skin complications of immunosuppression, especially warts, 
keratoses and cancers, were present in 249 patients (62.7%). Skin 
cancer was present in 17.6% of transplant recipients, all of whom 
were 5 or more years post-transplant. The squamousibasal cell 
carcinoma ratio was 8:1. HPV DNA was detected in 13 of 31 SCC 
samples analysed. In 6 cases, the HPV was HPV 20. 86% of the 
patients with skin cancers had high levels of lifetime occupational or 
social sun exposure.
Sun exposure, male gender and increasing graft survival time 
have emerged as major risk factors with minor influences from age 
and level of immunosuppression. No HI_A associations were found 
in the patients with malignancy in contrast to observations in kidney 
transplant patients.
Warts were found in 33.8% of patients, with a significantly 
higher incidence in males than in females, but were not influenced 
by levels of sun exposure.
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Organ transplant recipients experience a very high frequency of skin 
complications (1). In fact skin disease is the most frequent untoward 
effect experienced by most long-term transplant patients. 
Immunosuppression, human papillomavirus infection and sunlight 
exposure are thought to be the main risk factors responsible. To a 
smaller extent, HLA type and mismatch, age, sex and ethnic 
variations may play a part. The commonest long term skin 
complications are tumours, including both benign lesions such as 
warts and solar keratoses and also skin cancers such as basal cell 
carcinoma (BCC) and squamous cell carcinoma (SCC). Less common 
tumours include keratocanthoma, Bowen's disease, Kaposi's sarcoma, 
porokeratosis and anogenital malignancies such as cervical, vulval 
and anal cancers.
The short-term complications include infective lesions which may be 
bacterial, viral, fungal or protozoal in origin, and non-infective lesions 
caused specifically as a result of immunosuppressive therapy such as 
xerosis, cushingoid features, hypertrichosis, striae, facial erythema 
and friable skin (19). Short-term complications occur during the 
period immediately and few months posttransplant, mainly as a result 
of the reduced immunity, caused by high doses of 
immunosuppressants to prevent rejection and to ensure a smooth
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transition into the future. Long term complications are those which 
occur after the graft survival has exceeded five years. Post­
transplant, long-term skin tumours are a matter of concern in the 
longer term due to the following important differences from lesions 
occurring in the non-transplant population:
a. Their incidence is considerably higher (37, 45, 69).
b. Skin cancers occur 15-20 years earlier than their counterparts in a 
normal population (65, 71).
c. The spectrum of malignant and premalignant skin lesions in the 
posttransplant immunosuppressed is quite different (28).
d. Natural history of skin cancers in transplant recipients is more 
aggressive (7, 65).
e. They cause considerable morbidity since they can be resistant to 
treatment, and occur repeatedly.
f. Pre-malignant conditions like keratoses undergo accelerated 
progression to in situ invasive squamous cell carcinoma (50).
The data mentioned here are mainly derived from renal transplant 
recipients as they are the most extensively studied group. While 
there is some data in the literature relating to heart transplant 
patients, the risk and causative factors have not been clearly defined. 
One would expect them to have similar complications.
Recipients of heart, heart-lung and lung transplants form a rapidly 
growing cohort of patients. They generally receive higher doses of 
immunosuppressive drugs than renal transplant recipients and 
although the age range of heart transplants is comparable to the renal 
transplant recipients (23-58 years) heart-lung transplant recipients 
are generally much younger (20-40 years). Most of them are in their 
twenties and early thirties. Heart transplant recipients are
documented to suffer with similar types of skin problems to renal
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transplant recipients such as warts, skin cancers, solar keratoses (25, 
41) but the series reported to date are small. There are no published 
studies documenting the risk and spectrum of skin disease in heart- 
lung transplant recipients. This project involved a detailed study of 
thoracic transplant recipients at Papworth Hospital.
a Incidence and spectrum of post-transplant skin problems
Skin cancer
The incidence of post-transplant skin complications is greatest in 
areas with high intensity of sun exposure with rates increasing with 
time after transplantation. The incidence of post-transplant skin 
cancer in Australia has been reported to rise from 7% 1 year after 
transplantation to 70% 20 years post-transplant (14). Even in 
regions of temperate climate skin cancers are now a significant 
problem. European studies show a risk of development of SCC of 
10%, 10 years post-transplant increasing to 40% at 20 years (22, 
39, 49). The risk is greatest in Caucasians though even in white­
skinned populations, racial groups such as the Celts have a greater 
susceptibility to non-melanoma skin cancers (44). In the general 
population, basal cell carcinomas outnumber squamous cell 
carcinomas by 5-8:1. In transplant patients, the incidence of SCCs is 
increased 20 to 50 fold and BCCs is increased 10 fold over the general 
population (39). Hence, the ratio of the two cancers is reversed, with 
SCC : BCC varying from 1.8-3.6:1 (25, 37 39, 65). SCCs and BCCs 
occur on different sites, with SCCs occurring mostly on sun exposed 
sites such as the face and the back of the hands and BCCs also on the 
face, but also on the chest and back not on the backs of the hands. 
This probably demonstrates a difference in aetiology (39). A report 
published in 1991 from The Cincinnati Transplant Tumour Registry on
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over 5000 post-transplant cancers showed that cancers in recipients 
of non renal organs had a different pattern to that in recipients of 
renal organs. The commonest malignancy in non renal recipients was 
lymphoma whereas in renal graft recipients it was skin cancer (87). 
This discrepancy could have been due to the small numbers of non 
renal patients seen, since subsequent studies have shown a high 
incidence of skin cancer even in heart transplant recipients (25, 41). 
The incidence of lymphoma and Kaposi's sarcoma is higher in non- 
renal transplants than renal transplant recipients because of the 
intense immunosuppressive therapy they receive to reverse rejection, 
whereas renal transplants would revert to dialysis (65).
Premalignant lesions and warts
Warts can reach an incidence of 90% in patients 5-10 years post­
transplant (45, 69). The incidence of dysplastic epidermal keratoses 
in a prospective study of kidney transplant patients at a mean period 
of 2 years post-transplant, reached 14% (30). There is however 
evidence of accelerated progression of these lesions to malignancy 
(50). Factors, which could be involved in the transition of a 
premalignant lesion to a carcinoma, are activation of oncogene(s), 
inactivation of tumour suppressor gene(s), integration of HPV DNA 
into the host and failing immunity.
b. Risk factors
Immunosuppression
Some studies (3, 47) report that only the duration of
immunosuppressive therapy is significant for the development of skin 
complications but others report that the level is also important since
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reduction in the dose has been associated with a concomitant 
reduction in the multiplicity and rapidity of recurrence of skin cancers 
(11, 62). It is not known whether there is a certain threshold level of 
immunosuppression above which the incidence of skin complications 
ceases to increase any further. Comparisons between groups of 
transplant patients on different levels of immunosuppression would be 
needed to clarify this and hence, further studies are needed to 
establish the relative importance of dose and duration in this context. 
A recent Italian study (43) evaluated the first rejection score which 
was used as an indirect marker of the level of immunosuppression 
and which appears to be a better predictor of patients at risk for 
squamous cell carcinoma than cumulative immunosuppression. They 
concluded that both the level and duration of immunosuppression are 
relevant risk factors in the occurrence of SCCs. The duration of 
immunosuppressive therapy seems to be an important factor in 
acquiring SCCs but not BCCs (11) and BCCs tend to occur earlier in 
the course of immunosuppressive therapy as compared with SCCs 
(29). The number of episodes of rejection requiring short sharp 
bursts of immunosuppressive therapy does not seem to have any 
effect on the subsequent development of neoplasia (48). The 
occurrence of skin cancer and anogenital cancers is reduced according 
to some studies when cyclosporin based regimes are used, as 
opposed to those comprising azathioprine and steroids, even when 
different follow up times were considered (11, 64, 65). But other 
studies showed no difference (12, 14, 36) probably because at the 
time, cyclosporin was not in use for long enough to make any definite 
conclusions. The use of azathioprine is thought to be responsible for 
an increased risk of skin cancer due to the presence of its active 
metabolite 6-Thioguanine nucleotide in erythrocytes, supporting 
chemical carcinogenesis as a likely cause (46).
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Other forms of immunosuppressive therapy used are the monoclonal 
antilymphocytic agents, OKT3, ALG and ATG. These are used mainly 
as induction therapy and for episodes of refractory rejection. While 
there is little data on their possible cutaneous oncogenic potential, the 
use of OKT3 has been minimised in many centres because it has been 
shown to result in a high incidence of lymphoproliférative cancers 
(65). Further studies are required to define the risk of skin 
malignancies of this subgroup of very strongly immunosuppressed 
patients.
Ultraviolet light exposure
Sunlight is an important risk factor in the development of skin cancer 
and keratoses both in the immunosuppressed transplant patients and 
the nonimmunosupressed population (13, 47) whereas it is a risk 
factor for the occurrence of warts only in the immunosuppressed 
transplant population (13, 87). Viral warts in transplant patients are 
also significantly associated with pale skin which burns on ultraviolet 
light exposure (53). High exposure to sunlight before the age of 30 is 
more significant as a risk factor for the development of skin cancer by 
45 years, than exposure after the age of 30 (13). In contrast, there 
appears to be no association between life-time exposure to sunlight 
and the number of keratotic skin lesions (13). A recent study by 
Gallagher et al in the immunocompetent patient population suggests 
that recent sun exposure is more important than cumulative lifetime 
exposure in the development of skin cancers (32). The speed of 
development of skin cancers is related to the latitude of each 
transplant centre, skin cancers appearing earlier with decreasing 
latitude (20, 79). Ultraviolet light exerts its effects by damaging DNA 
leading to gene mutations in cutaneous cells which results in
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malignant transformation. Since U.V light induces cutaneous 
immunosuppression through various mechanisms such as affecting 
the function of antigen-presenting cells, inducing the release of 
cytokines and modulating the expression of surface molecules (88), 
the host is unable to recognise and destroy newly transformed cells. 
It also induces systemic immunosuppression by generating cis- 
urocanic acid close to the skin (58). This cumulative effect of U.V 
light induced coupled with drug-induced immunosuppression 
encountered in the transplant recipient could greatly amplify the risk 
of development of skin cancer. There are no studies so far that have 
defined this cumulative risk or have categorised people into high risk 
or low risk groups depending on their skin type, degree of sun 
exposure, family history and personal history. This needs to be 
studied in detail since it could be useful in instituting preventative 
measures in the high risk group.
Human Papillomavirus infections
Cutaneous lesions: Human Papillomavirus (HPV) infections like warts 
are the commonest post transplant complications. The HPV types 
implicated most commonly are HPV 2 and 4, occasionally other types. 
SCCs may follow warts after an interval of two to three years causing 
speculation that warts in immunosuppressed patients could predispose 
to malignancy, forming a continuum of disorders (13, 57, 83). This is 
however far from proven and is mere speculation. HPV has been 
implicated in the development of skin cancers in these individuals as 
it is found frequently in dysplastic and malignant squamous cell 
lesions (6, 27, 80). Earlier European studies (6, 26, 27, 29, 69, 85) 
reported HPV types 5 and 8 as being mainly responsible for skin 
cancer particularly SCCs. Australian studies however were not been 
able to substantiate this correlation (8, 23). It is not clear whether
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this discrepancy was geographical in origin . Five years later one of 
the European groups (6) found HPV types other than 5 and 8 in renal 
allograft recipients (77). This is possibly because of the development 
of more sensitive and specific present day techniques for HPV 
detection and analysis. HPV types that have been isolated by further 
refinement of laboratory techniques are 12, 20, 23, 38 and 2 novel 
types related to HPV 10 and 38 (21, 40). The fact that HPV types have 
been detected in some skin cancers and not others might mean that 
unidentified types could be present in HPV 'negative' lesions which 
require detection by further refinement of laboratory techniques or 
that they might be present only in low copy number and hence below 
the level of detection. McGregor et al. however believe that p53 
gene mutations are the major determinants of posttransplant skin 
malignancies as opposed to HPV induced p53 degradation and the 
presence of HPV in skin cancers is coincidental (51). p53 is believed 
to accumulate in skin cancers, specifically in areas of epidermal 
dysplasia but immunocytochemical staining has shown that there are 
factors other than p53 gene mutations which cause accumulation of 
p53 in skin cancers (78).
Important evidence of an association between HPV and both cancers 
and precancers comes from the histopathological examination of 
squamoproliferative lesions. The majority of them show cellular 
features of viral infection together with bowenoid changes and 
abnormal multinucleate cell (6, 67). This is in contrast to classical 
SCCs in the non immunosuppressed population. A recent study from 
the U.K however suggests that it is not possible to distinguish 
between squamoproliferative lesions in the immunosuppressed or 
immunocompetent on a histopathological basis (33). Strong evidence 
for the association of the cutaneous oncogenic potential of HPV is also
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evident from the occurrence of HPV types 5, 8, 9, 14, 17 and 20 in 
the SCCs of patients with the rare inherited condition
Epidermodysplasia Verruciformis (11, 39, 71). While there is no data 
on HPV association with skin cancer in heart and heart-lung 
recipients, the data on even more extensively studied kidney graft 
recipients remains inconclusive and the strength of the possible 
association requires additional study.
Anogenital lesions: Previous studies have shown a 14 to 16 fold 
increase in the incidence of cervical cancer (2, 63) and a 100 fold 
increase in the incidence of vulval and anal cancers (63) in renal 
transplant patients compared with the normal population. Genital 
cancers tend to occur later in the course of immunosuppressive 
therapies as compared to other malignancies. 'Low risk7 HPV types 6 
and 11 and oncogenic HPV types 16 and 18 have been implicated in 
the in the occurrence of cervical warts and all grades of dysplasia (2, 
55). HPV types 16/18 have been identified in anogenital and cervical 
carcinomas in most studies, thereby corroborating the functional role 
of human papillomaviruses in their development (84, 87). HPV is not 
only associated with cervical cancer but plays a definite aetiological 
role in the development of the disease. This role is further 
strengthened by the consistent detection of koilocytosis, a histological 
feature of viral infection, in genital lesions of immunosuppressed 
patients (13, 36). HPV 16 and 18 have transforming gene products 
such as E6 and E7 which interact with tumour suppressor proteins 
like p53 and PRB respectively and promote carcinogenesis. The 
mechanism of carcinogenesis if any, in skin cancers is likely to be 
different from HPV types 16 and 18.
21
A number of questions remain unanswered with regard to what extent 
the above risk factors contribute to the causation of skin cancers. 
There are suggestions from a few studies that the HPVs found in skin 
cancer have a low transforming potential and therefore are incapable 
of acting as carcinogens on their own. McGregor et at. hypothesise 
that viral infection cannot be the only causative factor in BCCs and 
SCCs by virtue of its presence alone, because it does not explain the 
predominance of SCCs over BCCs (52), although according to another 
school of thought only viral infection could explain the increased 
incidence of squamous cell carcinoma over basal cell carcinoma in 
transplant patients (47). The role of sunlight as a co-carcinogen in 
the development of skin cancers in transplant and non transplant 
patients is very well established by all groups.
Other risk factors
Age - It has been shown in renal allograft recipients that the risk of 
SCCs is greater in those transplanted after the age of 35 years (22, 
23).
HLA type - A Dutch study (17) showed increased risk of SCC with 
HLA-B mismatching and HLA-DR homozygosity in renal allograft 
recipients. Furthermore, positive associations with skin cancer has 
been found in these patients with HLA-B27 and HLA-DR7 (20) and a 
negative association with HLA-All (15). HLA-B mismatch and HLA- 
A l l  seem to have no effect on the occurrence of cutaneous warts 
(10). A recent Australian study (61) has shown that HLA-DR 
homozygosity was associated with skin cancer overall, HLA-DR7 was 
protective factor in skin cancer and HLA A1 and A l l  were protective 
factors in Bowen's disease. Two other studies (89, 90) failed to 
demonstrate a positive association with HLA-DR1 and A3 or a
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negative association with HLA-A11 in renal transplant patients with 
skin cancer.
Sex: Male recipients of kidney grafts are thought to have a higher 
incidence of skin cancer than females (47) but this conclusion was 
drawn without correction for UV exposure differences.
Ethnic variations: Higher prevalence of cutaneous cancers has been 
found in transplant recipients in South Wales as compared to rest of 
the U.K. probably owing to their higher proportion of Celtic ancestry 
(44).
Immunoglobulin levels: This has not been widely studied. Pollock et al 
(66) have shown higher incidence of skin malignancies in renal 
transplant recipients with low immunoglobulin levels.
c) Prevention and treatment options
Prevention : Prevention of cutaneous problems post-transplant is 
imperfect at this time. Patients should be educated about the 
importance of avoidance of UV exposure and the use of sun 
protection, but substantial damage to the skin may have been done in 
the years previously. However, findings of Gallagher et al (32) 
suggest that recent sun exposure may be more relevant than 
cumulative lifetime exposure, making it of paramount importance that 
this group of patients, should be strongly advised about sun 
protection and avoidance.
Treatment options: Oral retinoids have been used to reduce the risk of 
development of skin cancers in renal transplant recipients. The exact 
mechanism of action of the oral retinoids is unclear and different 
mechanisms have been suggested by various studies. One 
mechanism suggested is immunomodulation via stimulation of T-cell
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function which is an important component of their anti-tumour effect. 
Retinoids are also thought to have a direct effect on glycoprotein 
synthesis in epidermal cells and can induce tumour cell necrosis. 
Etretinate is also thought to act selectively on abnormal sun-exposed 
epidermis. Both controlled and uncontrolled studies of oral retinoids 
in renal transplant recipients suggest that they may cause regression 
of warts, keratoses and skin cancers without any significant adverse 
effects. Most patients do however experience side effects such as 
chelitis, generalised dryness and muscle aches (16, 76, 85). A 
controlled study has shown that oral retinoids in a dose of 30mg/day 
over 6 months can significantly reduce the incidence of keratotic skin 
lesions and prevent the occurrence of squamous cell carcinoma (16). 
Another recent study has also demonstrated the benefits of topical 
tretinoin, which with long-term use over a period 9 months, can 
prevent the occurrence of new lesions and reduce any existing ones 
(68). The use of retinoids may however be restricted in the heart 
transplant population who are at a greatly increased risk of 
accelerated atherosclerosis, as they result in elevation of serum lipids.
Surgical removal of skin tumours is sufficient in most patients, but 
therapeutic problems arise when lesions tend to be multiple and 
rapidly recurring. Extensive excision of severely dysplastic skin and 
grafting with non sun-exposed skin may be warranted in renal 
transplant recipients with SCCs, due to their aggressive nature.
The future
The future looks bright and a lot of work is presently being done to 
induce states of immune unresponsiveness directed towards foreign 
antigens of the allograft, thereby doing away with long term 
immunosuppressive therapy and making post-transplant malignancies
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a thing of the past. Future research will probably also look into 
interactions between viral and host-cellular proteins (52).
1.1.2 Human Papillomaviruses
Human papillomaviruses are small, non-enveloped, icosahedral, 
viruses that replicate in the nucleus of small epithelial cells. 
Papillomavirus particles are 52 to 55nm in diameter and contain 
circular, double stranded DNA of about 8000 base pairs (Figl). Even 
after their morphology came to light with the advent of the electron 
microscope in the 1960s, their characterisation took a while because 
they cannot be grown in tissue culture.
To date over 80 different of papillomaviruses have been isolated and 
characterised with the help of molecular biology techniques. Specific 
clinical entities caused by them have been defined. Papillomaviruses 
are species specific and have cellular trophism for squamous epithelial 
tissue. Susceptible cells respond to viral infection by causing cellular 
proliferation which is the fundamental nature of papillomaviruses ( Fig 
2).
The genome organisation of the majority of the HPV types consists of 
at least 7 early (E) genes (El to E7) and two late (L) genes (LI and 
L2). E genes are expressed early during the process of infection of an 
epithelial cell and the L open reading frames (ORFs) are expressed 
only in productively infected cells (Fig 1).
El and E2 are viral regulatory proteins, involved in viral DNA 
replication and viral transcription.
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E4 proteins complexes with cytokeratins and causes them to collapse. 
E5, E6 and E7 proteins of the papillomavirus have transforming 
activities through binding with p53 and pRB.
LI is the major capsid protein and L2 is the minor capsid protein. LI is 
500 amino acids in size, is highly conserved among the various 
papillomavirus types and is thought to mediate the major humoral 
and cell mediated responses to infection.
Histologically the lesions caused by human papillomavirus manifest in 
the following ways:
1. Thickening of the epidermis (acanthosis).
2. Hyperkeratosis.
3. Some amount of papillomatosis.





Genomic map of HPV type 16
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1.2 Aims of the study
The aims of this study are fourfold:
1. To define the risk of malignant and premalignant skin lesions in 
heart, heart-lung and lung transplant recipients and to determine the 
prevalence of warts and keratoses in this group of patients.
2. To evaluate the presence of human papillomavirus types in these 
lesions in such patients.
3. To correlate the level of immunosuppression and immunological 
events with the appearance of HPV and subsequent skin cancers.
4. To identify other significant risk factors in the development of skin 
cancers in these patients.
A total of 740 heart transplants, 230 heart-lung transplants, 102 
single lung transplants and 31 double lung transplants have so far 
been carried out at Papworth Hospital in the last 15 years. All 
surviving patients and medical records of those who died one or more 
years after transplantation were assessed with respect to skin disease. 
The clinical data analysis consisted of two major parts:
Retrospective analysis of patient data 
Data collection was been done by means of
a. Patient Questionnaire : This was completed by the patient and 
formed the basis of the initial assessment. The information obtained 
helped in identifying patients with specific skin problems, in particular 
problems such as viral warts, keratoses and skin cancers and gave 
some indication of potential risk factors including exposure to
28
ultraviolet radiation and family history. Questionnaires were collected 
from all surviving transplant recipients.
b. Patient records : Detailed data was collected from patient records 
held at Papworth hospital and supplemented with information 
obtained on request from the patients' physicians. Data collection 
was done to assess the role of various risk factors in causing the skin 
lesion.
c. Interview and examination : Patients were seen individually and 
further details documented of life-time sun exposure, pre-transplant 
skin disease, development of skin cancers, warts and pre-cancerous 
lesions post-transplant. Examination of patients' skin helped in both 
qualitative and quantitative assessment of skin disorders, at least at 
one time point for each patient.
Determination of the role of HPV
a. Analysis of diseased tissue: Scrapings or biopsied specimens from 
all existing and new cutaneous lesions such as warts, keratoses and 
skin cancers were processed for the type and presence of HPV.
Most studies so far have focused on long term skin complications in 
kidney transplant patients. There are few studies on the spectrum and 
incidence of skin problems encountered in heart transplants and 
practically none in the heart-lung and lung transplant group. They 
differ from the kidney group in the following ways.
a. Heart transplant recipients are very often more ill pretransplant
b. Immunosuppression tends to be higher in heart transplant patients 
than kidney transplant patients and even higher in the heart-lung 
group.
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c. Heart-lung transplant patients are younger than the heart and 
kidney transplants.
Since there have been no conclusive results from various studies on 
the presence of human papillomavirus in skin cancers especially SCCs, 
it was a useful outcome of the study to document this in the heart 
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Laboratory methods were used for the purpose of detecting human 
papillomavirus DNA within the skin tumours of thoracic transplant 
recipients. DNA was extracted from tissue for amplification by 
polymerase chain reaction. Tissue was available in different 
conditions: a) formalin-fixed, paraffin-embedded biopsies, b) fresh, 
frozen biopsies and c) fresh wart parings. Different extraction 
methods were applied, as detailed in sections 2.1.1.a, 2.1.1.b and
2.1.1.C respectively.
DNA extraction was followed by the polymerase chain reaction in 
which target DNA sequences are amplified through repeated cycles of 
denaturation, annealing with primers complementary to flanking 
regions of the target sequence and finally DNA synthesis. This 
produces enough DNA to be tested adequately because it amplifies a 
single DNA molecule into billions of molecules. Each temperature 
cycle requires between 1-5 minutes. Thus 20-50 cycles are needed to 
produce the desired molecular sensitivity take 2-4 hours. A typical 
PCR amplification is capable of producing 1012 molecules of HPV 
amplified DNA per lOOpI of reaction.
The development of the polymerase chain reaction, in vitro gene 
amplification technology, is a major virological advance in molecular
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biology. The polymerase chain reaction is considered the method of 
choice for detection of human papillomavirus in clinical samples 
because of its sensitivity and significantly reduced assay time. 
Amplifying the fragment required and visualising it on agarose gel is 
possible in a matter of just a few hours.
Techniques such as Southern blot, filter and in situ hybridization have 
been used in the past with great success but they have their 
limitations because of the large amount of DNA material required for 
HPV detection and therefore their use is limited in archival specimens. 
The maximum overall prevalence of HPVs has been seen with PCR. 
The polymerase chain reaction thus seemed the most suitable 
technique for the study.
34
2.1.1 DNA Extraction from tissue
2.1.1.a DNA Extraction from paraffin tissue
The paraffin blocks containing embedded fixed biopsy tissue together 
with the clinical and histopathological report were obtained from the 
patient's dermatologist or via the histopathology department.
25pim sections were cut on the micrometer and 2 sections were stored 
in a 1.5 ml eppendorf tube. To avoid contamination, a plain wax 
block was cut in between different tissue blocks, and a separate blade 
was used for each block and the cutting surface cleaned regularly with 
xylene. The sections were stored at room temperature.
Protocol a)
1. Paraffin was removed from sections by the addition of 300pl of 
xylene. After 2 minutes, the mixture was centrifuged briefly 
and the xylene removed.
2. 300pl ethanol was added, to remove the remaining xylene, and 
then discarded. Residual ethanol was evaporated from the 
tissue sections by incubation at 55°C with an open lid.
3. 50pl of DNA extraction buffer (50mM Tris HCI pH 8.5, 1M EDTA,
0.5% Tween 20) plus 1.3pl of proteinase K stock solution 
(20mg/ml) were added to digest the DNA and incubated at 55°C 
overnight.
4. The proteinase K was inactivated by incubation at 95°C for 10 
minutes.
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5. The samples were rapidly cooled on ice and stored at -20°C 
until use. 5pl of this digested mixture was used in a PCR 
reaction.
Solution used:
x 20 Extraction Buffer
50mM Tris HCI, pH 8.5
1M EDTA
0.5% Tween 20
pH adjusted to 8.5 with HCI
Protocol b)
1. Sections were deparrafinated as described in steps 1-2 of 
Protocol a)
2. PCR reagents were added directly to the dewaxed tissue. 
(Anticipated success rate for optimal 5 square mm of section is 70%)
Protocol c)
The tissue was treated as in steps 1-5 of Protocol a) and then a a 
phenol / chloroform / ethanol extraction was performed as described 
in part 2.1.1.b below.
All 3 methods were tried in order to determine the most suitable 
method which gave the best results. Protocol a) gave the best results 
and was finally used for all the samples.
2.1.1.b DNA Extraction from frozen tissue
1. Fragments of frozen tissue were homogenised in 1ml of 'Frozen 
Tissue Buffer' and rapidly refrozen.
2. lOOpI of 10% SDS and 20pl of proteinase K (lOmg/ml) were 
added and the tissue digested at 50°C for 5-16 hours.
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3. The resulting digest was divided equally into two, and each 
mixed with an equal volume of phenol. The aqueous phase, 
containing DNA, was removed and the remaining phenol 
dissolved with addition of chloroform.
4. The upper aqueous phase was again removed and mixed with 
three times the volume of ethanol and one tenth the volume of 
3M Sodium acetate, pH 4.8. The solution was frozen at -20° C 
overnight or -70°C for half an hour and then spun for half an 
hour and the pellet visualised.
5. The ethanol was removed, the pellet rinsed in 70% ethanol, 
vaccum dried and resuspended in 30pl TE buffer or water after 
which the was subjected to PCR amplification.
Solutions used:
Frozen Tissue Buffer
0.5 M Tris HCI 
0.1 M Na acetate 
0.2 M EDTA
The final pH of the solution was 8.0.
10% Stock solution of sodium sarcosine 
10 g of N-lauryl sarcosine was added to a final volume of 
100 ml of water and dissolved overnight to make a 
10% solution.
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2.1.1.C DNA extraction from wart parings and frozen wart samples 
from patients in routine dermatology clinics.
The efficacy, sensitivity and specificity of the primers and the PCR 
reaction was assessed from wart specimens obtained from routine 
dermatology clinics.
Wart parings were washed in 1 ml cold lysis buffer and resuspended 
in 450pl of cold lysis buffer and 50pl of lysis solution which contains 
Proteinase K for DNA extraction. The DNA solution from the frozen 
samples was also treated with a phenol / chloroform / ethanol 
extraction as described in 2.1.1.b.
Solutions used:
Lysis Buffer




12.5pl of 20mg/ml of Proteinase K 
30pl of 10% SDS
TE Buffer (10:1)
10ml 1M Tris-HCI, pH 8.0 
2ml 0.5M EDTA 
Distilled water to 1000ml
0.5 M EDTA, pH 8.0
Phenol TE-saturated phenol (Sigma) was aliquoted and 
stored at -20°C.
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2.1.2 Polymerase Chain Reaction
The PCR reaction mixture consisted of the following:
Constituents 50ul reaction 20ul reaction
mixture mixture
1. x 10 PCR Buffer 5pl 2pl
2. 25mM MgCI2 5pl 2pl
3. 2mM dNTP 7pl 2.5pl
4.Oligonucleotide primer 1 2pl 2pl
5. Primer set 2 2pl 2pl
6. Taq Polymerase enzyme lpl lpl
7. DNA solution 5pl 2pl
8. Water 23pl 6.5pl
The components were mixed gently before placing in the 
thermocycler. Temperature cycling was done according to the 
following steps of 30 cycles each. The number of cycles set are 
determined by the amount of template DNA in the reaction, with less 
template DNA the number of cycles need to be increased.
1. Initial denaturation, which is of paramount importance, was done 
for 1 minute at 95°C. This is so because a complete denaturation 
results in more efficient utilisation of the template and therefore a 
better yield of the PCR product. Taq Polymerase was usually added 
before the start of the PCR since it was only at 95°C for 1 minute. If 
the Taq polymerase is subjected to that temperature for longer 
periods it loses its stability, despite its relative thermostable nature. 
Taq DNA polymerase has a propensity for adding non-templated
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nucleotides to the 3' end of DNA chains. This can result in problems 
during cloning the PCR product.
2. Annealing was done for 1 minute at 56°C. This is usually 
determined by the GC content of the primers used. If the GC content 
is less than 50%, annealing is done at 55%, if the GC content is more 
than 50%, annealing is done at 60°C. This step ensures that the 
primers anneal to the template stably.
3. Extension was set at 72°C for 1 minute. This is determined by the 
expected product length. If the expected product length is <= 500, 
extension is one minute. For products >500 nucleotides, extension is 
3 minutes.
4. The extension time was further increased to 7 minutes at 72°C to 
ensure the full length of the PCR products.
5. The holding capacity of the PCR thermocycler is 99 hours and the 
samples could be kept for that length of time at 4°C but in practice 
was no more than 16 hours.
The conditions of the polymerase chain reaction had been used in the 
laboratory for amplification of HPV DNA. For the purposes of 
amplifying DNA from tissue, the conditions were not changed as they 




2mM solution of dIMTP was made from lOmM of dATP, dCTP, 
dGTP and dTTP. lOOmM stock solution of the above was diluted 
to lOmM.
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2.1.3 Agarose Gel Electrophoresis
A 1% multipurpose agarose horizontal mini-gel was prepared and 
submerged in TBE buffer. DNA samples with 1/6 volume of the DNA 
loading buffer were loaded into the wells. A current of 70mA was 
passed across the gel for half an hour.
Method
1. 10ml of TBE Buffer was diluted with 90 ml water.
2. 0.50 gms of the multipurpose agarose was added to 50ml of 
the diluted buffer solution. Ethidium bromide l-2pl at a 
concentration of 25mg/ml was added to the remaining buffer.
3. The agarose mixture was heated, cooled and added to the gel 
tank to set and then the diluted buffer solution added over the 
set gel before application of current.
Solutions used 
TBE Buffer xlO 
89mM Tris base 
89mM boric acid 
2.6mM EDTA
pH adjusted to 8.3 with HCI 
DNA loading buffer
0.25% Bromophenol Blue (runs at 400 bp)
50mM EDTA
30% Glycerol
0.04 M Tris HCI, pH 7.0
0.02M sodium acetate
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1 kb ladder Stock solution (lug/ul) diluted 1:20 in DNA 
loading buffer.
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2.1.4 DNA purification and Gel Extraction
This is done for the efficient purification of PCR products from
amplification reactions and to contribute as a first step in DNA
purification towards the final step of DNA sequencing.
Method of gel extraction
1. 42pl of a 50pl PCR reaction mixture was mixed with 5pl of loading 
dye and subjected to electrophoresis in a 1% agarose mini-gel.
2. The DNA band was visualised under low wavelength UV light and 
the gel cut just in front of the DNA band in order to insert a small 
strip of treated DEAE paper.
3. The gel was run for a further 15-20 minutes and confirmation that 
the DNA had transferred on to the paper was obtained by 
visualisation under UV light.
4. The DEAE strip was rinsed in NTE1 solution to remove agarose and 
then placed in 500pl NTE 2 solution and incubated at 50° C for 30 
minutes. This incubation was performed so that the DNA would 
be eluted from the DEAE paper and into solution.
5. The paper was transferred to a fresh eppendorf tube, and given a 
final wash with 50pl of NTE 2 which was added to the 500pl NTE 2 
buffer.
6. Of this 550pl, 225pl was subjected to a phenol/chloroform/ethanol 
extraction. The DNA was precipitated with 2.5 times the volume of 
ethanol (1250pl) and 3pl 3M NaAc.
7. The DNA was kept at -70°C for half an hour, centrifuged for 10 




DEAE paper was cut into strips and washed for 10 minutes in lOmM 
EDTA (pH 7.6), 5 minutes in 0.5 M NaOH and then in distilled water 










2.1.5 Cloning with a TA Cloning Kit
The TA Cloning Kit (Invitrogen) was used to clone the products of PCR 
amplification. The DNA obtained by PCR from tissue was ligated after 
gel extraction into a pCR vector and then transferred into competent 
E.coli cells.
2.1.5. a Addition of overhangs post amplification
Usually if Taq polymerase is used for the PCR reaction the cloning 
efficiency is good and the 3' A-overhangs are not removed. If 
however the blunt-ended fragments need to be cloned, the following 
need to be added:
1. Add lpl of Taq polymerase per tube was added and incubated on 
heat block equilibrated to 72°C for 10 minutes.
2. The DNA was extracted with equal volume of phenol/chloroform, 
1/10 volume 3M Sodium acetate and twice the volume of absolute 
ethanol then added. The mixture was centrifuged, the DNA pellet air 
dried and resuspended in 40pl of water. The addition of 3'A overhangs 
was done only in a few samples. The procedure did not add to the 
cloning efficiency and so was not adopted as a routine.
2.1.5. b Ligation reaction
A lOpI ligation reaction mixture was prepared
1. Fresh PCR product 2pl
2. xlO Ligation Buffer lpl
3. pCR 2.1 vector 2pl
4. Sterile water 4pl
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5. T4 DNA Ligase l|jl
Total volume lOpI
Ligation reactions were incubated at 14° C overnight.
Precautions taken
1. No more than 2-3pl of the PCR in the ligation reaction was used so 
that T4 DNA ligase was not inhibited by salts in the PCR
2. The ligation reaction was kept at 14°C to maximise the accuracy of 
the ligation efficency.
2.I.5.C. Transformation
Two types of cells are provided with the TA Cloning kit - INV ALPHA F'
- TOP 10 F'
Before starting with the Transformation reaction the following steps 
were taken:
1. A water bath was heated to 42°C, a vial of SOC was thawed and 
brought to room temperature.
3. The plates made of a mixture of 2TY+ ampicillin in agar were taken 
out from the cold room and kept at 37° C and then brought to room 
temperature.
4. 40pl of 40mg/ml of X-Gal was added to each plate and then spread 
evenly.
5. Whenever TOPIOF’ competent cells were used, 40pl of a lOOmM 
ITPG solution was added to the plate along with X-Gal. This was to 
enable blue-white screening of bacteria containing inserts in the 
vector. The liquid was properly soaked on to the plates.
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Method
1. The ligation reactions were centrifuged for a few seconds and kept 
on ice.
2. A vial of 0.5M 13-mercaptoethanol and competent cells were thawed 
for each transformation.
3. 2pl of 0.5M B-mercaptoethanol was added to the vial of competent 
cells and mixed by stirring gently with the pipette tip.
4. 2pl of ligation reaction was added into the cells and mixed gently.
5. Vials were kept on ice for 30 minutes, heat shock given for 30 
seconds in a 42°C water bath, and then put back on ice for 2 minutes.
6. 250pl of the SOC medium (provided with the kit) was added at 
room temperature to each tube and the vials were kept in a 225rpm 
shaker at 37° C for 1 hour.
7. 50pl and 200pl of each transformation mix was spread on to 
separate labelled plates. Plates were inverted and left for an hour 
before overnight incubation at 37°C.
Analysis of the Transformants
1. Each transformation reaction was analysed for the presence and 
number of white colonies and overnight cultures were set up for 
plasmid isolation.
2. White colonies were picked from sites closest to blue colonies.
3. Colonies were grown in 2-5 ml of 2TY broth to which 50pg/ml of 
ampicillin was added. Incubation was done either by means of a wire 
loop or sterile pipette tips and kept overnight in a shaker for good 
agitation.
Difficulties encountered and Precautions taken
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1. White colonies did not always have an insert. A repeat 
transformation with another tube of the vector was performed.
2. Only white colonies without any blue colonies were obtained. IPTG 
may have been inadvertently omitted.
3. White colonies of normal size were surrounded by smaller white 
colonies. These are satellite colonies and were not picked as they did 
not have insert.
4. Sometimes very few white colonies were obtained and majority of 
the colonies were blue or light blue.
This could be due to a number of reasons:-
- The PCR products were kept for a long time before the ligation 
reaction and that could have reduced the efficiency.
- Too much of the amplification reaction was added to the ligation; 
not more than 2-3pl needed to be used.
Solutions used
Stock solution of Ampicillin (5mg/ml water). Stored in 
aliquots at - 20°C.
Stock solution of X-gal at 40mg/ml in dimethylformamide. 








2.1.6.a Mini-Prep methods for the Overnight Cultures
Two different methods were used for the preparation from bacteria 
and screening of plasmid DNA. The DNA produced by Method 1 was 
of inadequate purity for sequencing and so a second method was 
adopted.
Method 1
1. Bacteria in 3ml of broth cultured overnight were pelleted by 
centrifugation for 1 minute and the supernatant discarded.
2. lOOpI of lysis solution was added to the pellet and the bacteria 
resuspended.
3. 200pl of alkaline-SDS solution was added, mixed and left on ice 
for 2 minutes.
4. 150pl of high salt solution (3M sodium acetate, pH 4.8) was added, 
mixed thoroughly and left on ice for 45 minutes. The mixture was 
vortexed every 15 minutes.
5. After centrifugation in a microfuge for 5 minutes, the supernatant 
was transferred to a fresh eppendorf tube and 1ml of cold ethanol 
was added, mixed thoroughly and left on dry ice for 10 minutes.
6. The mixture was centrifuged 5 minutes and the supernatant 
discarded. The DNA pellet was rinsed with 95% ethanol, dried and 
redissolved in 0.2ml 0.1M sodium acetate, pH 7.0. The DNA was 
reprecipitated with 0.5ml cold ethanol at -70°C for half an hour or - 
20°C overnight.
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7. Finally the solution was centrifuged for 15 minutes and the pellet 
rinsed with 70% ethanol, dried in a dessicator and dissolved in 30- 
40pl sterile H20.
Solutions used 
Alkaline SDS solution 
20ml of 1M NaOH 
10ml of 10% SDS 
Distilled water to 100ml
Method 2
The other method used was a Wizard Mini-prep kit. This gave DNA of 
pure quality which could be sent off for sequencing directly.
1. Cells were pelleted from 2ml of overnight culture and resuspended 
in 200pl of cell resuspension solution. 400pl of Neutralisation solution 
was added and mixture centrifuged for 5 minutes to obtain a clear 
lysate.
2. The cleared lysate was transferred to a fresh tube to which 1ml of 
Wizard miniprep resin was added and mixed.
3. The mixture was transferred to a Wizard mini column and liquid 
removed by vacuum.
4. The resin was washed with 2ml of 40% isopropanol/4.2M guanidine 
hydrochloride, especially for end A strains and then with 2ml of 
column wash solution.
5. 40pl of water was added and after 1 minute, the eluted DNA was 
collected by microcentrifugation for 20 seconds.
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2.1.6.b Eco RI Check Digestion
A restriction enzyme digestion was performed and the DNA visualised 
under UV light after electrophoresis in an agarose gel. This was done 
as a check to visualise and therefore to confirm the presence of DNA 
in the mini-prep, sample before sending it off for sequencing.
Mini-prep DNA sample 15pl
Eco R1 enzyme (20,000 iu/ml) lpl 
xlO digestion buffer 2pl
RNase lpl
H20 lpl
Incubation: 37° C for an hour.
Measurement of DNA
The amount of DNA present in the sample was determined 




Sequence data was obtained, with the help of M13 toward and reverse 
universal primers. The DNA was sequenced using 2 different 
automated sequencers. Both of them were supplied by Perkin-Elmer 
Applied Biosystems and sequencing was performed in the 
Biochemistry laboratories.
1. ABI Applied Biosystems Prism 373 XL -15 hour run.
2. ABI Applied Biosystems Prism 377 XL - 8 hour run.
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2.1.8 Sequence Analysis
A search was performed to find a homology between the sequences 
obtained from positive DNA samples and those present in the EMBL 
database. The programme used for the search was Fasta and that was 
provided in the software by Wisconsin Package version 9.1, Genetics 
Computer Group (GCG), Madison, Wisconsin.
Another programme from the same package called Gap was utilised 
which uses algorithm of Needleman and Wunsch (48) to find the 
alignment of two complete sequences that maximises the number of 
matches and minimizes the number of gaps.
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2.1.9 Materials
General purpose reagents were supplied by Sigma, Boehringer 
Manheim, East Anglia Chemicals, BDH Chemicals, Fisons, Pharmacia, 
AnalaR and Bethesda Research laboratories (BRL).
Gibco BRL Custom primers (Nested primer pair - CP) were obtained 
from Life Technologies, Ltd. Primers and were designed according to 
the Berkhout nested primers. (10).
Degenerate Shaminin (Sha) primers were obtained from Perkin-Elmer 
Applied Biosystems UK and were designed according to the German 
group to enable detection of a broad range of papillomavirus types 
(9).
Both the above were designed from the LI region of the Open Reading 
Frame since that is the most conserved region among the various HPV 
types.
Primers were supplied lyophilised and resuspended at a concentration 
of 10 pmol/pl (forward primer) and 10 pmol/pl (reverse primers) prior 
to use.
Enzymes






Alignment of sequences of Human papillomavirus 8 with 
homology to the oligonucleotide Berkhout primers.














Table 1. Oligonucleotides used for the polymerase chain reaction
Primer name Sequence 5’-3’ Primer Length
CP 65 CAR GGT CAY AAY AAT GGT GGY AT 20
CP70 AAY TTT CGT CCY ARA GRA WAT TGR TC 20
CP 66 AAT CAR MTG TTT RTT ACW GT 20
CP 69 A TCW GTY ATR TCT ACA TYC CA 20
CP 62 GTW AAT GAA AYT TGY AAA TAT CC 23
Sha B5 CTG GAT CCA YNC CRT TRT TRT GNC CYT G 28
Sha B6 CTG GAT CCA YNC CRT TRT TYT GNC CYT G 28
Sha B 11 CTG GAT CCA YNC CRT TRT TYG TNC CYTG 28
Sha FP CTG GAT CCT CNM GNG GNC ANC ANC CNY 28
TNG G
beta globin F GAA GAG CCA AGG ACA GGT AC 20












Plan of work: A total of 740 heart transplants, 230 heart-lung 
transplants, 102 single lung transplants and 31 double lung 
transplants have so far been carried out at Papworth Hospital in the 
last 15 years. All surviving patients and medical records of those who 
died one or more years after transplantation were assessed with 
respect to skin disease. The clinical data analysis consisted of two 
major parts:
2.2.1 Retrospective analysis of patient data
Data collection was done by means of
2.2.1.a Patient Questionnaire (Appendix 1)
This was completed by the patient and formed the basis of the initial 
assessment. The information obtained helped in identifying patients 
with specific skin problems, in particular, problems such as viral 
warts, keratoses and skin cancers and gave some indication of 
potential risk factors including exposure to ultraviolet radiation and 
family history. Patients during their regular follow-up appointments 
completed questionnaires. Those who had filled in questionnaires 
more than two years before the data was analysed or those who had 
never filled in one were sent out a questionnaire by post to ensure 
that no skin lesion was omitted. The questionnaires were sent back 
promptly in most cases. Questionnaires were collected from all 
surviving transplant recipients.
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2.2.1. b Patient records
Detailed data was collected from patient records held at Papworth 
hospital and supplemented with information obtained on request from 
the patients' physicians. The other means of data collection was 
medical notes and the Papworth transplant database. Previously 
removed skin cancers and keratoses, wherever diagnosed, were 
reviewed histologically by a histopathologist. Data collection focused 
on the assessment of the role of various risk factors in causing the 
skin lesions. These were:
1. Drug history in the context of dose and duration of cyclosporin, 
prednisolone and azathioprine.
2. Episodes of rejection that needed treatment with anti-rejection 
drugs such as OKT3, ATG and methyl prednisolone.
3. History of lifetime sun exposure and sun protection.
4. Family history of warts, skin cancers and keratoses.
5. HLA typing of the donor and the recipient.
6. Demographic data such as age, sex and ethnic variations.
2.2.1. c Interview and examination:
Ethical committee approval was obtained prior to the start of the 
project. Patients were seen individually and further details 
documented of life-time sun exposure, pre-transplant skin disease, 
development of skin cancers, warts and pre-cancerous lesions post­
transplant. Examination of patients' skin helped in both qualitative 
and quantitative assessment of skin disorders, at least at one time 
point for each patient. Information was recorded about skin lesions 
included type, site and duration. At the same time, any suspect skin 
lesions were removed. Skin lesions that were removed included 
mainly warts (common and flat) and keratoses. The skin cancers that
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were examined in the study had been removed by dermatologists and 
plastic surgeons at different places in the country, so paraffin blocks 
were obtained directly from the patients' histopathologists.
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2.2.2 Determination of the role of HPV
2.2.2.a Analysis of diseased tissue
Scrapings or biopsy specimens from all existing and new cutaneous 
lesions such as warts, keratoses and skin cancers were processed for 
analysis of the presence and type of HPV using methods described in 
section 2.1.
Prospective analysis for appearance of HPV
In order to study the temporal acquisition (or rate of activation) and 
the role in disease of HPV types associated with dysplastic or invasive 
malignant squamous epithelial lesions, a prospective study of the 
post-transplant appearance of HPVs in the skin of these 
immunosuppressed patients was commenced. Scrapings were
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3.1 Laboratory - DNA analysis from fixed tissue.
3.1.1 PCR of DNA extracted from paraffin blocks 
sections.
Tissue blocks of skin lesions were obtained and DNA extracted for PCR 
amplification. Of the 40 samples available, 31 were subjected to a 
complete DNA analysis. The samples were all between 2-10 years old 
and the patients were between 5-15 years post-transplant. 
Histopathological examination by the initial reporting pathologist 
showed that the the lesions were diagnosed variously as squamous 
cell carcinomas, basal cell carcinomas, Bowen's disease, solar 
keratoses and Bowenoid actinic keratoses. The DNA from samples the 
with histology described as SCC, BCC, Bowen's disease, keratoses or 
Bowenoid actinic keratoses were subjected to a two-step PCR reaction 
with a nested primer pair to amplify cutaneous HPV DNA. 13-globin 
primers were used as an internal positive control for each of the 
reactions and to test whether DNA of adequate quality was extracted 
from the fixed tissue.
The results of the PCR amplification using p globin primers and nested 
HPV primers are shown in Table 2. For each PCR reaction a positive 
and a negative control was used. The negative control was wax and 
the positive control was genomic HPV DNA or a positive sample which 
had been positive three times. When a positive PCR result was
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obtained, the reaction was repeated to a maximum of three times to 
verify the consistency of the results.
The expected product size in the PCR reaction with the nested primer 
pair was approximately 470 bp. A positive band in this region present 
consistently after three PCR attempts was taken as a positive result. 
The presence of the band once and absence on two occasions was 
treated as a negative result. The B-globin primers which amplify a 
268 base pair region were positive in all the samples which gave 
positive results with the nested primer pair. There were also positives 
for some for which DNA was not amplified with the nested primer pair. 
This is possibly indicative of the fact that although there is some DNA 
present in the samples it is degenerate and of insufficient quantity to 
give a positive result with primers which amplify a larger base pair 
region.
Parameters which affect the PCR reaction were kept in mind and the 
following precautions were taken :
1. Temperature cycling - Denaturation was done at 95° C for 1 
minute, annealing at 56° C for 1 minute and extension at 72°C for 1 
minute. These conditions were not altered.
2. MgCI2 concentration - The concentration of MgCI2 was optimised at 
25mM. Decreasing the concentration below this gave a poor yield of 
the PCR product.
3. Amount of DNA solution used - Too much of the template DNA 
solution used may increase the chances of contamination. Since PCR 
causes greatly increased amplification, a very small amount is 
needed.
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4. dNTP Large amounts of dNTP can inhibit the activity of Taq 
polymerase enzyme and the concentration of the nucleotides was kept 
constant at 2Mm.
5. Primer Design - The primers used had already been designed by 
other groups according to the following set of rules.
a. The primers were selected to bind in the LI ORF of the HPV 
genome, since the LI is the most conserved region between 
different HPV types.
b. The primers were designed be 18-25 nucleotide bases in length, 
too long a length can result in mismatch and non-specific 
amplifications.
c. The ends of the primer should end in a G or a C or GC or CG to 
increase the efficiency of priming but at the same time more 
than 3 G or C nucleotides should be avoided to prevent non 
specific priming.
d. Primer 3'-ends should not have complementary base pairs to 
avoid primer-dimer synthesis.
e. The composition of G and C nucleotides should be about 50% 
and should be distributed uniformly throughout the full length.
6. Taq Polymerase - More than lul of Taq polymerase in a 50pl
reaction can cause synthesis of non-specific products
The samples were coded with the first letters of the last name of the 
patient and the kind of lesion present.
1. Squamous cell carcinoma - S
2. Basal cell carcinoma - B
3. Bowens disease - Bo
4. Actinic keratoses - AK
5. Warts - W
6. Bowenoid actinic keratoses - BAK
e.g. John Smith with a squamous cell carcinoma= Sm/S
David Jones with 2 squamous cell carcinomas= Jo/Sl, Jo/S2
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DNA was extracted from a total of 31 lesions from 11 patients. 7 of 
the patients had only one tissue biopsy, 1 patient had 2, 1 patient had 
4, 1 had 5 and 1 had a total of 10 separate lesions. Of the 31 lesions 
tested, 8 (25%) gave negative results with p- globin primers and also
with HPV primers. Of the 22 lesions positive with p-globin primers
16(72%) showed amplification of HPV DNA after the second round of 
PCR using the nested primer pair. Patients in whom several lesions 
were tested showed both positive and negative HPV results in 
different lesions.
Examples of the results of PCR amplification of extracted DNA are 
shown in Figure 3 (HPV primers) and Figure 4 (p-globin primers)
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Fig 3
Results of nested PCR on SCC samples, wax being the negative control and 
So/S4 the positive control
DNA product of PCR amplification of SCC samples using primers CP 
65/70 and CP 66/69A.
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PCR reaction of deparrafinated SCC samples with beta-globin primers
Kg 4
Positive results in the SCC samples with 6-globin primers in the 268 
bp region. On this occasion, positive PCR product was seen in 
samples Br/S, Gi/Sl, Gi/S4, Gi/S5, Ha/S2, Ha/S3, Mn/S and Pa/S. 
Gi/S5 and Gi/S7 were negative.
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Table 2. Table showing PCR results with nested/ 13-glob primers
P a t ie n t
s a m p le
A g e  
A t  T x
S ite  o f  
le s io n
T im e  p o s t -  
T r a n s p la n t  
(9 8 )
N e s te d  p r im e r  
p a ir s
G g lo b in  p r im e r s
La/S 55 face 6 positive positive
Me/S 48 e ar 9 positive positive
H a / S l 54 Face 8 positive positive
Ha/S2 54 Lip 8 positive positive
Ha/S3 54 Lip 8 n e g a tive positive
H a/S4 54 Lip 8 n eg a tive positive
Br/S 53 Face 9 n eg a tive positive
W r/S 47 N ose 8 n eg a tive n eg a tive
5 o / S l 47 N ose 14 positive positive
5o/S2 47 E a r 14 p ositive positive
5o/S3 47 Face 14 n eg a tive positive
5o/S4 47 face 14 positive positive
3 i/ S l 57 S ca lp 9 positive positive
3i/S2 57 Face 9 positive positive
3i/S3 57 Face 9 n eg a tive positive
3i/S4 57 Face 9 positive positive
3i/S5 57 C h e s t 9 n eg a tive positive
3i/S6 57 Face 9 n eg a tive n eg a tive
3i/S7 57 Face 9 positive positive
3i/S8 57 sca lp 9 n e g a tive positive
:a/s 56 Face 11 p ositive positive
:w a/si 47 E a r 7 n eg a tive n eg a tive
:W a/S2 47 Leg 7 positive positive
la/A 56 Face 11 n eg a tive n eg a tive
:a/B2 56 C h e s t 11 positive positive
:a/B3 56 C h e s t 11 n eg a tive n eg a tive
:a/BAK 56 A rm 11 n eg a tive n eg a tive




Gi/Bo 57 Leg 9 n eg a tive n eg a tive
Sy/B 41 Earlobe 7 n eg a tive n eg a tive
Pa/S 49 Face 12 positive n eg a tive
The table depicts the patients last name initials and type of skin 
lesion present, age at transplant, site of the cancer or keratoses and 
time post transplant when the data was calculated and paraffin blocks 
of lesions were worked on. It also shows the PCR results with the 
nested primer pair and beta-globin primers on paraffin samples.
S-SCC, B-BCC, AK- Actinic keratoses, BAK-Bowenoid actinic keratoses, 
Bo-Bowens disease.
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3.1.2 Mini-prep of the positive PCRs of the paraffin block 
sections.
DIMA was amplified using the nested HPV primers from 16 samples. In 
each case the PCR products were cloned with the help of a TA cloning 
kit. Ligation reactions were set up, followed by transformation and 
then the transformants were cultured overnight. Mini-preps were 
done for all the positive samples according to the methods listed in 
Chapter 2 and were checked for DNA yield by an Eco RI digestion. 
Examples of positive results are seen in Figs 5, 6 and 7.
Mini-preps of samples Gi/S4 and Gi/S7 
Gi/S4 Gf/S7
3 5 1 2 3 4
470bp
Fig 6
Results of mini-preps of samples CWa/S2 
and Ha/S2




Results of Eco digestion of sample So/S4 after mini-prep
2 5 6
DNA product of PCR amplification of S0/S4 extracted DNA using 
primers CP 65/70 and CP 66/69A was cloned into TA cloning vector. 
Following transformation, DNA was extracted from bacterial colonies 
and subjected to digestion with Eco Rl. DNA was visualised in an 
agarose gel. The digestion produces a band of 470 base pairs which is 
visible in clones 2, 5 and 6.
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3.1.3 DNA Sequencing and Sequence Analysis
Of the 16 samples positive with PCR, 13 were sent for sequencing to 
the Department of Biochemistry. In 3 samples, there was insufficient 
DNA for sequence analysis. Of those sequenced, HPV types were 
sequenced in 6 samples. No HPV was sequenced in the rest. 
Interestingly HPV 20 was sequenced in each of the 6 samples. This 
is an Epidermodysplasia Verruciformis related HPV type (42).
Nucleic acid sequences of the sequenced samples La/S, So/Sl, Gi/S7 
are illustrated in Figs 8, 9 and 10. The other samples sequenced for 
HPV 20 were Ha/S2, So/S4 and Gi/S4.
As a result of a search done in Gap package, a high percent identity 
was found between DNA sequenced from the 6 samples and the LI 
ORF of HPV 20 (Fig 11).
HPV 20 is 7757bp in length and was first isolated from skin warts of 
patients with epidermodysplasia verruciformis and subsequently from 
a few SCC patients. Even among the EV patients along with EV types 
14, 17 and 47, it has been found in few skin cancers as compared 
with HPV types 5 and 8.
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Figure 8.
NUCLEIC ACID SEQUENCE OF La/S
1 CTCGAGCGGC CGCCAGTGTG ATGGATATCT GCAGAATTCG GCTTATCAGC 
51 TGTTTGTTAC AGTAGTAGAT AATACTCGAA ATACAAATTT TAGCATATCA 
101 GTTCATTCAG AAAACACTGA TGTTTCTAAA ATTCAAAATT ATGACTCTCA 
151 GAAATTTCAA GAATATTTAA GACACGTAGA AGAATATGAA ATTTCATTAA 
201 TTTTACAGCT CTGTAAAGTT CCTTTAACAG CTGAAGTTTT AGCTCAAATT 
251 AATGCTATGA ATTCAAATAT ATTAGAGGAG TGGCAGTTAG GATTCGTTTC 
301 TGCACCGGAT AATCCTATCC ACGATACATA CAGATATATT AATTCTGCAG 
351 CTACTAGATG TCCTGGTAAA AATCCTCCAA AAGAAAGAGA AGATCCTTAC 
401 AAGGATCTAA ACTTCTGGAA TGTAGACATA ACAGAAAGCC GAATTCCAGC 




NUCLEIC ACID SEQUENCE OF SO/SI
1 TACCCCNANC TGCCAAAAGG GGGATGTNTT NCAAGCCGAT TAAGTGGGGT
51 ACCGCCAGGG TTTTCCCAGT CACGACGTNG TAAACGACGG CCAGTGAATT
101 GTAATCCGAC TCCACTATAG GCGANTTGGC CNTCTAAATG CATGTTCGAN
151 CGGCCCGCAG TGTGATGAAT ATCTGCAGAA TTCGGGCTTA TCAGCTGTTT
201 GTTNCAGTAG TAGATAATAC TCGAAATNCA AATTTTAGCA TATCAGTTCA
251 TTCAGAAAAC ACTGATGTTT CTAAAATTCA AAATXATGAC TCTCAGAAAT
301 TTCAAGAATA TTTAAGACAC GGTAGAAGAA TATGAAATTT CATTAATTTT
351 ACAGCTCTGT AAAGTTCCTT TAACAGCTGA AGTTTTAGCT CAAATTAATG
401 CTATGAATTC AAATATATTA GAGGAGTGGC AGTTAGGATT CGTTTCTGCA
451 CCGGATAATC CTATCCACGA TACATACAGA TATATTAATT CTGCAGCTAC
501 TAGATGTCCT GGTAAAAATC CTCCAAAAGA AAGAGAAGAT CCTTACAAGG































































































Alignment o f nucleic acid sequences o f HPV 20 L I compared with Gi/S7, 
La/S and So /Sl
Figure 11
HPV 20 ATCAAC TAT T TG T TAC TG TAG TAGATAATAC TC GAAATACAAAT T
i i i i i i  i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i  i i i i i i
Gi/S7
II II II 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 II 1 1 1 1 
ATCAGCTGTTTGTTACAGTAGTAGATAATACTCGAAATACAAATT
1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1
La/S ATCAGCTGTTTGTTACAGTAGTAGATAATACTCGAAATACAAATT 
M  I I I I  l l l l I l l l l l l I I  I I  l l l l M  M  l l l l I I  1 l 1 1 1 1
So/Sl




1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
T TAGCATAT CAGT T CAT T CAGAAAACAC T GAT GT T T C TAAAAT T C 
I l I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 1 1 I I  l 1 1 1 1
La/S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
TTAGCATATCAGTTCATTCAGAAAACACTGATGTTTCTAAAATTC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
So/Sl T T AGCATAT CAGT T CAT T CAGAAAACAC T GAT GT T T C TAAAAT T C
HPV 20 AAAATTATGATTCTCAGAAATTTCAAGAATATTTAAGACACG TAG
i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
Gi/S7
1 1 II 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I  
AAAAT TAT GAC T C T CAGAAAT T T CAAGAATAT T T AAGACAC G TAG 
l l l l l l l l l l l l l l l 1 l l l 1 l 1 l 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I
La/S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I  
AAAAT TAT GACT CT CAGAAAT T T CAAGAATAT T TAAGACAC G TAG 
l l l l l l l l l l l l l l l l l l l l l l 1 l 1 l l l l 1 l 1 1 1 1 1 1 1 1 1 1 I I I
So/Sl
1 1 1 1 1 1 1 1 1 1 II 1 II 1 II 1 1 1 1 1 1 1 1 1 1 1 II II 1 1 II 1 1 1 1 I I I  
AAAATTATGACTCTCAGAAATTTCAAGAATATTTAAGACACGGTAG
HPV 20 AAGAATATGAAATTTCATTAATTTTACAGCTCTGTAAAGTTCCTT
i i t i i t t t t t i i i i i t i i i i i i i i i i i i i i i t i i i i i i i i i t i i i
Gi/S7
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
AAGAATATGAAATTTCATTAATTTTACAGCTCTGTAAAGTTCCTT 
I I I I I I I I I I I I I I I I I I i i  i i  M  I I I I I I I I I l l I I I I l l l l l l
La/S
1 1 1 II 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 
AAGAATATGAAATTTCATTAATTTTACAGCTCTGTAAAGTTCCTT
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 II 1 1 1 1 1 1 II II 1 1 1 1 1 1 II 1 1 1 II 1
So/Sl AAGAATATGAAATTTCATTAATTTTACAGCTCTGTAAAGTTCCTT
HPV 20 TAACAGCTGAAGTTTTAGCTCAAATTAATGCTATGAATTCAAATA
i i i i i i i i i i i i i i i  i m  i i i i  i i i i i i i i i i i i i  i i i m  i i i m
Gi/S7
1 1 1 1 II II 1 II II 1 1 II 1 1 1 1 II 1 1 1 1 1 1 1 1 II 1 1 II II II 1 1 1 1 
TAACAGCTGAAGTTTTAGCTCAAATTAATGCTATGAATTCAAATA
1 1 1 II 1 II 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 II 1
La/S TAACAGCTGAAGTTTTAGCTCAAATTAATGCTATGAATTCAAATA 
I M I I I M I l l I M l I I M M M l II l II II II I l II l l l l II II
So/Sl
II 1 1 1 1 1 1 1 1 II 1 II 1 II 1 II II II II 1 1 1 1 1 1 1 1 1 1 1 1 II II 1 1 
TAACAGCT GAAGT T TTAGCT CAAAT TAAT GCTAT GAATT CAAATA
HPV 20 TATTAGAGGAGTGGCAGTTAGGATTCGTTCCTGCACCGGATAATC
Gi/S7
1 II 1 1  III 1 1 1 1 1 1  1 1 11  1 1 1 1 1 III 1 1 1 II 1 1 1 II II 1 1 1 II 1
TATTAGAGGAGTGGCAGTTAGGATTCGTTTCTGCACCGGATAATC 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
La/S TATTAGAGGAGTGGCAGTTAGGATTCGTTTCTGCACCGGATAATC




I I II I I II II I II I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I
GÍ/S7 CTATCCACGATACATACAGATATATTAATTCTGCAGCTACTAGAT
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
La / S CTATCCACGATACATACAGATATATTAATTCTGCAGCTACTAGAT
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I
So/Sl CTATCCACGATACATACAGATATATTAATTCTGCAGCTACTAGAT
HPV 20 GTCCTGATAAAAATCCTCCAAAAGAAAGAGAAGATCCTTACAAGG
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I
GÍ/S7 GTCCTGGTAAAAATCCTCCAAAAGAAAGAGAAGATCCTTACAAGG
I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
La / S GTCCTGGTAAAAATCCTCCAAAAGAAAGAGAAGATCCTTACAAGG
I I I I I I I I I I I I I I I I I I II I I I II I I I I II I I I I I I I I I I I I I
So/Sl GTCCTGGTAAAAATCCTCCAAAAGAAAGAGAAGATCCTTACAAGG
HPV 20 ATCTAAACTTTTGGAATGTTGACCTATCAGAAA
I I I I I I I I I I I I I I I I I I III II I I I I II
GÍ/S7 ATCTAAACTTCTGGAATGTAGACATAACAGAAA
I I I I I I I I I I I I I I I I I I III II I I I I I I
La/S ATCTAAACTTCTGGAATGTAGAÇATAACAGAAA
I I I I I I I I I I I I I I I I I I III II I I I I I I
So/Sl ATCTAAACTTCTGGAATGTAGAÇATAACAGAAA
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3.1.4 PCR of the frozen tissue normal skin samples 
At the time of the start of the project, several HPV types had been 
detected in skin cancers of renal transplant patients and the number 
reported are rapidly growing. Then, as now, the role of the viral DNA 
in the development of such tumours was unclear. The carriage rate of 
the viral DNA in patients had not been specifically shown to increase 
with time post transplant and it was uncertain if the virus was already 
present pre-transplant but activated by immunosuppression or 
whether it was acquired after transplantation when immune resistance 
was reduced. In order to try to address the question of when such 
viral DNA could be acquired, we hypothesised that HPV DNA would be 
detectable on clinically normal skin of immunosuppressed individuals 
and that the viral load would increase with time post-transplant. If 
this was the case, HPV DNA should be more readily found in 
individuals a few years after a transplant, but perhaps not so easily 
found in individuals early post-transplant. We therefore sought to 
perform PCR amplification on skin scrapings taken from clinically 
normal skin of transplant recipients and to analyse such samples in 
relation to time post-transplant.
DNA was extracted from the following samples which had been 
collected from the patients, labelled as below and frozen at -70°C and 
subjected to a phenol/chloroform extraction and ethanol precipitation 
before PCR amplification.
Different variations of the methods of DNA extraction from tissue and 
PCR amplification were tried using frozen wart biopsy tissue so as to
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optimise the best method for the small tissue samples taken from 
normal skin. The variations tested included:
1. Varying concentrations of magnesium chloride in the PCR reaction.
2. Using different detergents such as Sodium sarcosine, Triton X 100 
and SDS in the proteinase K digestion.
3. Grinding frozen samples with/without dry ice.
4. Addition or omission of sonication of a sample prior to protease 
digestion.
Results
1. Increasing the quantity of 25mM Magnesium chloride from 1.6pl to 
2.0 to 2.4pl increased the amount of DNA amplified.
2. Positive results were obtained with use of detergent Sodium 
sarcosine and SDS but not with Triton X 100.
3. Samples ground with dry ice gave positive results but not so in the 
case of the samples which were not ground.
4. Sonicating the sample did not make any difference to the results.
The PCR results from normal tissue are shown in Table 3
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Table 3. PCR results of normal skin samples
itient sample 
ĝe/Sex
S ite  co llected  
from
R e su lts  o f  PCR  
w ith n ested  p rim e r  
p a ir
R e su lts  o f P CR  w ith  
beta g lob in  p rim e rs
R e su lts  o f PCR  
w ith S h a m a n in  
p rim ers
1 /52 yrs/F N orm al sk in  / 
arm
N e g a tiv e N e ga tive N e ga tive
.2 /43 yrs/M N orm al skin  
/hand
Positive Positive Positive
.3 /54 yrs/M N orm al sk in  / 
fa ce
Positive Positive Positive
.4/58 yrs/F N orm al skin  
/arm
P ositive Positive Positive
i.5/43yrs/M N orm al sk in  / 
foo t
P ositive Positive N e ga tive
>.6/46yrs/M N orm al sk in  / 
hand
N e g a tive Positive N e ga tive
Normal skin samples were collected from these patients varying from 
immediately post transplant to 10 years post transplant. The idea was 
to look for the presence/absence of HPV on normal skin and therefore 
to determine at what point, if at all HPV is activated on to the skin. It 
was however not possible to determine the HPV types in the positive 
samples because of time constraints.
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Fig 12.
PCR of frozen norma! skin samples S.3 and S.4 with nested 
primer pair CP62/70 and CP65/69 and Shaminin primers
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Figure 12 illustrates the example of positive results with PCR, both 
with the nested primer pair and Shaminin primers. The Shaminin 
primers amplify a 650 bp region in the LI ORF. They are degenerate 
primers designed originally by a German group (72) which identify a 
wide variety of HPV types. They are suitable for use on fresh and 
frozen tissue and plasmid DNA only because of the longer length of 
DNA amplified, which makes them unsuitable for use in paraffin 
embedded tissue.
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The nested primer pair used in this case for normal skin samples was 
modified in that CP 62 and CP 70 were the outer primer pair and CP65 
and CP 69 were the inner primer pair (18). The primer pair is slightly 
different from the one used for fixed tissue sections with CP 62 being 




The total number of patients analysed in this study was 397; 296 
heart transplant patients, 90 heart-lung transplant patients and 11 
lung transplant patients. Both the heart-lung and lung transplant 
patients were grouped together because they receive similar levels of 
immunosuppression. They will be referred to as the lung group. All 
patients were taking corticosteroids and azathioprine. Most, but not 
all, were also taking cyclosporin.
3.2.1 Prevalence data
Prevalence rates were estimated as the number of patients with the 
outcome divided by the number who returned questionnaires. 95% 
confidence intervals were calculated as a measure of the precision of 
the estimates.
3.2.1.a Warts
a. The overall prevalence of warts in all groups was 33.8%.
b. The prevalence of warts in the heart group was 47% (confidence 
interval 41% to 53 %).
c. The prevalence of warts in lung transplants was 33% (confidence 
interval 24 %to 42%).
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3.2.1. b Keratoses
a. The overall prevalence of keratoses was 17%.
b. The prevalence of keratoses in the heart patients was 18% 
(confidence interval 14% to 22%).
c. The prevalence of keratoses in lung transplant patients was 14% 
(confidence interval 7% to 21%).
3.2.1. C Skin cancer
a. The overall prevalence of skin cancer was 17.6%
b. Hearts - 20% (15 to25% confidence interval).
c. Lungs-10% (confidence interval of 4% tol6%)
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Figure 13
Prevalence of skin lesions in heart and lung 
transplant patients
Warts Keratoses Skin cancer
The incidence of skin cancer in East Anglia in 1995 was 0.22%. The 
incidences of the above skin complications could not be calculated 
because the time that the lesion occurred post transplant was not 
accurately provided by patients through the questionnaire and also 
because lesions had been treated in different parts of the country. 
However it may be expected that the prevalence and incidence are 
not greatly different, particularly in the case of skin cancers as these 
are usually treated within a short period of being detected.
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When compared with studies on kidney transplant patients the 
prevalence of skin cancer varied. In a study by Bouwes-Bavink (14) 
the prevalence of skin cancer was 24.7% (271/1098). In a Spanish 
study the prevalence was only 1.6% (8/497). This difference could 
however be because of shorter follow up time periods. Another 
Spanish study (25) of heart transplant recipients showed a prevalence 
of 15%, which is within the confidence limits of this study.
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3.2.2 Correlation with risk factors
In order to investigate the risk factors for the outcomes, we studied 
both transplant factors and environmental factors. Environmental 
factors were age, gender, occupational and social exposure to 
sunlight, use of sun protection, skin type and hair colour and family 
history of warts and skin cancer. Transplant factors studied were type 
of transplant, dose of immunosuppressive therapies and the number 
of treated rejection episodes in the first 3 months after transplant, the 
period of greatest immunological onslaught.
Methods used
Initially each categorical risk factor was tabulated against the 
outcome measures and Pearson's chi-squared statistical test was 
applied to assess the significance of any associations.
For continuous, normally distributed measurements such as patient 
age and drug dosages, mean and standard deviations were calculated 
as summary statistics and Student t-tests were used to assess 
significance. Where appropriate, the analysis was repeated for heart 
and lung transplants separately; for example, these groups use 
different definitions of acute rejection. Univariate analysis however 
only takes into account one variable at a time.
Finally, multivariate logistic regression was used to determine those 
variables which were independently associated with the outcomes.
The rationale for multivariate analysis would be to identify the 
smallest group of factors which would help predict the risk status of 
patients following cardiothoracic lung transplantation.
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Odds ratio and 95% confidence intervals were calculated, whereby the 
odds on each outcome for a group of patients is compared with the 
same odds for a baseline group. If the odds ratio is 1 the groups have 
the same chance of having the outcome. An odds ratio which is 
significantly greater than 1 indicates that the test group are at greater 
risk of the outcome than the baseline group. Conversely, an odds 
ratio of less than 1 means that the test group have a lower risk of the 
outcome. For example, an odds ratio of 2 indicates that the test 
group are twice as likely to have the outcome as the baseline group. 
Logistic regression was done separately for skin cancers, warts and 
keratoses to look at the association with skin type, sun protection, 





Category Warts Keratoses Cancer
Type Of Tx (H) P=0.013 P=0.35 P=0.021
t Age P=0.304 P=.0002 P=0.002
Sex ÎM P=0.010 P=0.387 P=0.0007
HLA B27 P=0.838 P=0.504 P=0.755
HLA DR7 P=0.664 P=0.589 P=0.561
HLA A l l P=0.348 P=0.894 P=0.710
Rej P=0.092 P=0.779 P=0.608
Pred i P=0.031 P=0.708 P=0.648
Aza i P=0.304 P=0.265 P=0.361
CyA i P=0.292 P=0.230 P=0.241
Occup t P=0.089 P=0.205 P=0.212
Social t P=0.333 P=0.324 P=0.015
Sun Protection t P=0.323 P=0.025 P=0.095
Skin types i  1, 2 P=0.266 P=0.030 P=0.072
Hair colour P=0.757 P=0.446 P=0.659
F/H burns t P=0.003 P=0.778 P=0.858
F/H warts P=0.019 P=0.470 P=0.297
F/H cancer t P=0.167 P=0.0085 P=0.916
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Logistic Regression-Table 5
1. Warts 95% Cl
Variables Exp Lower Upper Result
Type of Tx 1.5479 .8949 2.6775 Fleart t
Sex 1.8776 1.0319 3.4162 Malest
Pred .1697 .0094 3.0650 T Pred i  
risk
F/H Burns .5739 .3612 .9120 No history 
i  risk
F/H warts .4905 .2549 .9439 No history 
i  risk
2. Keratoses-Table 6
Variables Exp Lower Upper Result
Type of Tx .8250 .3758 1.8114
Age 1.0772 1.0392 1.1165 T age trisk
Aza .7103 .4753 1.0615
Cyc 1.0456 .9708 1.1262
Skin type 1 3.0279 .3731 24.5765
Skin type2 1.8856 .8724 4.0758
Skin type 3 .8841 .4275 1.8281
F/H Cancer .2423 .0919 .6389 No history 
of Ca 4 risk
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3. Skin cancer-Table 7
Variables Exp Lower Upper Result
Type of Tx .8043 .3449 1.8755
Age 1.0442 1.0125 1.0769 t age T risk
Sex 5.3046 1.5218 18.4911 Males T risk
Social exp .5026 .2581 .9788 No exposure i  
risk
Protect 1 .4693 .2069 1.0648
Protect 2 .9266 .4472 1.9198
Skin type 1 4.1957 .5072 34.7059
Skin type 2 1.4349 .5806 3.5462
Skin type 3 1.6696 .8533 3.2669
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3.2.2.a Gender
a. Warts - Overall 37% of males and 23% females developed 
warts post transplant. The difference was statistically significant with 
a p value=0.015.
b. Keratoses - Overall 17.7% of males and 14% of females 
transplanted developed keratoses.
c. Skin cancer - 21.6% of males and only 3.4% of females
developed skin cancer post transplant. This reached a statistical 
significance of p<= 0.001.
3.2.2.b Age
a. As expected, increasing age was a risk factor for the occurrence 
of keratoses and skin cancer but not warts.
b. The difference in the mean ages of patients with skin cancer 
(48.34) and without skin cancer (42.04) reached a statistical 
significance of p=0.0002.
The difference was similar in patients with keratoses and reached 
statistically significant levels of p=0.0002.
3.2.2.C HLA associations
No positive statistically significant associations were found with HLA 
B27 or HLA DR7 or negative associations with HLA A l l  in the case of 
warts, keratoses or skin cancers.
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3.2.2.d Immunosuppression
a. Episodes of rejection in the first few months which need 
treatment with heavy doses of immunosuppressants is one of the the 
markers for immunosuppression. This however was not a risk factor 
in the occurrence of warts, keratoses or skin cancers in this study.
b. An unexpected result of the statistical data analysis in the lung 
transplant group was that patients with lower levels of prednisolone 
had a higher occurrence of warts and patients receiving lower doses of 
azathioprine had a somewhat higher prevalence of keratoses.
c. No other significant associations were seen.
3.2.2.e Sun exposure and skin type
a. Higher degrees of occupational exposure to the sun had an 
increased correlation with the occurrence of warts, although this was 
not statistically significant. In this group the low risk group sun 
exposure group was used as the baseline group with an odds ratio of 
1. The moderate risk group had an increased risk of developing warts 
by 1.23 times over the baseline group. The high risk sun exposure 
group had a further 1.23 times increased risk over the moderate risk 
group. High sun exposure could be a relevant factor in the occurrence 
of warts in the transplant group although this is not so in the case of 
the normal population. The patients were grouped into low, moderate 
and high sun exposure groups depending on the amount of sun they 
received by virtue of their occupation exposure. There were no other 
variables included in this risk categorisation
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The commonest sites for the occurrence of warts were the dorsum of 
the hand followed by the face and then the feet. The commonest 
treatment modality if taken was liquid nitrogen followed by topical 
therapy (paint) and then curettage and cautery. There was usually 
good response to treatment with liquid nitrogen. The commonest 
group of patients however, were those who did not take any sort of 
treatment. No significant correlation was found between high degrees 
of occupational sun exposure and increased occurrence of keratoses 
and skin cancers in the present study.
b. Social exposure to the sun which includes activities such as sun 
bathing was a definite risk factor in this study for the increased risk of 
skin cancer. This correlation had a statistical significance of p=0.015.
c. As expected, patients with skin types 1 and 2 were more 
predisposed to the development of keratoses, p=0.030, and skin 
cancer, p=0.072. There was, however, no correlation in the case of 
warts.
d. The commonest skin cancer was SCC followed by BCC and then 
Bowen's disease. SCCs were mostly present on the face. The 
commonest site for the occurrence of BCCs was the chest and back. 
They were usually treated with surgery.
3.2.2.f Family History
a. One of the interesting aspects of the study is that a family 
history of a tendency to sunburn particularly in Skin types I and II 
had a significant correlation with the occurrence of warts post­
transplant (p=0.003)
b. A family history of skin cancer contributed significantly to a risk 
of keratoses but not skin cancer (p=0.0085)
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c. As expected, a family history of warts was a risk factor in the 
occurrence of warts post-transplant (p=0.019).
The p value is a probability with value ranging from zero to one. It 
answers the questions of whether differences observed in different 
population samples reflects a true difference or is a coincidence of 
random sampling. If the p value is small, it is possible to conclude 
that the difference is unlikely to be caused by random sampling. 







In this study of heart and lung transplant recipients, we have 
assessed the size of the problem of long-term skin complications and 
the potential role of certain risk factors. The skin complications cause 
morbidity and distress to the patients as well as increasing the 
dermatological workload on the health service. One of the major aims 
of this thesis work was to define the risk of skin cancers in heart, 
heart-lung and lung transplant recipients and to try to evaluate the 
relative importance of various potential risk factors for cutaneous 
malignancy in this population.
Using patient questionnaires, examination and molecular analysis of 
archival material, this study has focused on the development of skin 
complications and the role of various risk factors such as 
immunosuppressive regimes, sun exposure, gender, age, ethnic 
variations and also examined the role played by human 
papillomaviruses, if any, in causing post-transplant skin cancer in a 
cohort of heart, heart-lung and lung transplant recipients.
About 1100 patients underwent organ transplantation at Papworth 
Hospital since 1979. Of the 730 heart, 220 heart-lung and 130 lung 
transplants carried out at Papworth hospital since 1982, detailed 
information was obtained from 397. Skin complications such as skin 
cancer, warts and keratoses were present in a total of 249 (62.7%) 
patients. Warts were present in 172 patients, skin cancers in 70 and 
keratoses in 67. This information was gathered from several sources; 
patient-completed written questionnaires, hospital records and from 
interview and examination of patients. The most accurate way to
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gather such data would be by means of all three methods for each 
patient. This was not possible for all patients in this population of 
transplant recipients due to time and geographical constraints.
The development of malignancy is known from other studies to be a 
significant risk during long-term immunosuppression. In this group of 
heart and heart-lung transplant patients, skin cancer was the most 
commonly occurring cancer, and was present overall in 17.6%. The 
ratio of occurrence of SCC: BCC was 8:1. The ratio in other studies on 
renal and thoracic organ transplants varies anywhere from equal to 
15:1 (6, 7, 25, 34, 39). The median age of patients who had skin 
cancer was 48 years, which was younger than the 54 years reported 
in a recent Australian study of heart transplant recipients (69). 
Although these tumours can cause severe morbidity and some 
patients needed radical neck dissection and radiotherapy, none of the 
patients in the present study group died of metastatic skin SCC. This 
is probably owing to the fact that these patients were followed up well 
and presented early as they were aware of the complications. In a 
study (7) from Cincinnati 3 patients out of the 44 patients with 
epithelial skin cancers developed lymph node metastases and 1 
eventually died as a result of skin disease. There is however no 
evidence to suggest that these patients were not followed up well or 
that they were not aware of the risks of skin cancer. The inference is 
that the natural history of skin cancers in the immunosupressed organ 
transplant patients is more aggressive than in patients without 
immunosuppression or transplantation. The historical aspect that 
people were not aware of skin cancer after transplant 20 years ago, 
could have influenced the development of cancers in a group of 
people who have received transplants relatively recently.
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The prevalence rate of skin cancers of 20% in the heart transplant 
patients and 10% in the heart-lung transplant group in this cohort of 
thoracic transplant recipients was compared with results from the 
previous studies in kidney and heart transplant patients. In a 
Norwegian study (41), which looked at 122 heart patients, the period 
prevalence of skin cancers was 12.9%. A Spanish study (25) of heart 
transplant recipients showed an incidence of skin cancer of 15.2%. 
The incidence of skin cancer in a Scottish study (6) of 202 renal 
transplant patients, 5 years post transplant was 12%. The incidence 
was less, possibly because of reduced exposure to ultraviolet radiation 
as compared with places like Spain and Australia. A Dutch study (39) 
in post renal transplant patients showed an incidence of 10% of skin 
cancer at 10 years post-transplant and 40% at 20 years post­
transplant. An Australian study (38) showed a cumulative risk of 23% 
at 5 years post renal transplant due to the subtropical locale. The 
variations in the prevalence and incidence from different studies are 
probably due to a combination of different factors such as age, 
different levels of ultraviolet light exposure, variations in the 
immunosuppressive regimes, race, skin type and the time that the 
tumour occurred post-transplant.
The present study supported the idea that several factors were 
interrelated for the development of skin cancers. Ultraviolet light 
exposure particularly in the form of social activities such as 
sunbathing, older age at transplant, immunosuppression, skin types 1 
(burns easily, tans poorly) and 2 (tans after a little burning) and time 
post-transplant were all interrelated. The prevalence of skin cancers 
in heart transplant patients was double that in heart-lung patients 
mainly because they are in an older age group even though the 
immunosuppression levels were similar or less. The risk factors above
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are in keeping with most other studies, in renal and heart transplant 
recipients.
47% of heart transplant patients and 33% of heart-lung and lung 
transplant patients had warts. The prevalence of warts in heart 
transplant patients in a Norwegian study was 42.6% which was within 
the confidence limits of this study. Only half of the 70 skin cancer 
patients had warts and in the same way half of the patients with skin 
cancer had keratoses. This does not tie in well with the hypothesis 
postulated by some groups (57) that patients with greater number of 
warts were at a greater risk of developing SCCs and was not the case 
in this study. Most of the warts in the present study were on sun 
exposed sites such as the face, hands and arms. The transformation 
in the case report (57) from warts to SCCs was on sun-exposed sites, 
mainly hands and face. Although no such parallel was seen or 
reported in the present study regular dermatological examinations of 
warts on sun exposed areas should be carried out.
All the sections analysed by PCR had been examined histologically by 
the histopathologist at the referring hospital. Since histopathologists 
do not always make precisely the same diagnosis of tissue biopsies, 
especially when the disorder might be part of a spectrum of, in this 
case, epidermal change, it would be of value for the tissue diagnosis 
to be reviewed by at least one other pathologist.
HPV DNA was detectable in a proportion of archival tissue samples 
using degenerate primers and was detected in 13 of the 31 samples. 
Of those 13 samples positive for HPV, 6 gave adequate sequence data 
and in each case it was HPV 20. The finding of exactly the same type
102
of HPV in 6 samples raises the doubt that a single contaminant caused 
the positive results in these 6 samples.
This is despite the fact that all precautions were taken to minimise 
contamination. This was done by means such cutting sections by 
using a fresh microtome blade and avoiding repositioning for fresh 
samples because even that is prone to contamination. In fact, the 
tissues were scraped by hand by means of a surgical blade for half the 
paraffin blocks. The fixed tissues are harder than wax and scraping 
them made the sample more exact. Besides avoiding contamination 
this also takes care of the problem of normal adjoining tissue and 
other types of tissue interfering with the polymerase chain reaction. 
Contamination during the Polymerase chain reaction was kept to a 
minimum by careful use of the Gilssons and putting blank tubes 
between normal ones during the PCR run.
Other studies have shown a higher positive rate of HPV detection 
ranging from 20% to 80% in skin cancers (6, 20, 72) and in normal 
skin (18) depending on the primers and the techniques used. Our 
study results are different, and suggest a much lower rate of detection 
(19%) of HPV DNA despite a much larger number of positive |3-globin 
amplifications which determines the adequacy of the sample to a 
large extent. This could be because the use of fixed archival tissue 
makes PCR amplification more difficult. Another reason could be 
because of the time factor. There was not enough time to try other 
methods such as using primers which amplify a lower basepair region 
and verify the results obtained. There are however ways which could 
improve the detection rate. It is possible that the HPV types were 
present in low copy numbers, so we could only be certain about their 
presence and further role in causing skin cancer after designing
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primers which amplify a 100-200 basepair length of DNA. It would 
also be useful to work on frozen tissue samples of skin cancers since 
DNA in them is not degenerate, thus the chances of detecting HPV 
DNA are doubled (54). More normal skin samples need to be studied 
to look for HPV in them, high proportion of virus in normal skin makes 
it a less likely to be a high risk factor for progression to malignancy. 
This study was unable to demonstrate either a negative or positive 
association between skin cancers and Human papillomaviruses. The 
number of samples analysed were insufficient and even among the 
positive results we could not be sure if all the samples were HPV 20 
since the chances of contamination cannot be ruled out.
The preliminary results of DNA amplification of HPV DNA from 
scrapings of clinically normal skin in transplant recipients suggested 
that 4 out of 6 (67%) patients were harbouring viral DNA on the skin 
surface. Since this study was initiated, there have been several 
studies reporting the presence of HPV DNA, as detected by PCR, on 
the skin and in the hair follicles of both immunosuppressed and also, 
to a lesser degree, immunocompetent individuals(18). Although it was 
only possible to perform PCR on 6 such patients, our limited results 
support the concept that HPV DNA is widespread in transplant 
recipient skin. Given more time, it would be important to sequence 
the DNA detected to ascertain the specific type involved in these 
cases. The rate of positivity of the skin scrapings was much higher 
than the rate of HPV positivity in the tissue biopsies. This may be due 
to the greater ease of extraction of DNA suitable for PCR amplification 
from frozen as opposed to fixed tissue. Detection of HPV DNA from 
skin scrapings or indeed analysis of plucked hairs in transplant 
patients would give a means of analysing HPV acquisition over time 
post-transplant. It would also be of interest to know if the HPV types
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found on the clinically normal skin of a transplant patient are the 
same types as those found in the same patient's skin malignancies or 
pre-malignancies.'
Sun exposure has emerged as a major risk factor as in previous 
studies (13) and use of sunscreens in this group of transplant patients 
has not proved particularly beneficial as patients who used more sun 
protection still had keratoses and skin cancer. This could however be 
because people who had a tendency to skin cancers and sunburn 
tended to use more sunprotection. Sunscreens are known to slow the 
development of keratoses (6) and to reduce sunburn but it is not 
known to what extent they prevent local immunosuppression which is 
thought to be a contributory factor in the pathogenesis of skin cancers 
(76).
Smoking is considered a risk factor in the occurrence of skin cancer 
(18) but this was not taken into account in this study.
No HLA associations of any sort were found unlike in some previous 
studies (17) in kidney transplant patients, so presence of HLA-B27 
and HLA-DR7 and the presence or absence of HLA-All was not 
considered to confer a protective effect on the occurrence of skin 
cancer (15). The study had enough power to study HLA associations.
The study is likely to have less than 50% power to detect 
relationships between HLA mismatches at the A, B and Dr loci and 
skin lesions. It is very difficult to establish these kinds of relationships 
in data from a single centre. Relationships between HLA mismatches 
and mortality have been established from registry data comprising 
several thousands of transplants but results from individual centres
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vary widely. This is because of the following reasons: first, the effect 
of HLA mismatches are small and modified by many other 
confounding factors so that large series are required to delineate the 
effects. Second there is no prospective HLA matching in heart and 
lung transplantation due to requirement for short ischaemic times, 
resulting in the vast majority of patients having more than 2 
mismatches at these 3 loci.
While the risk of lymphoma is known to be increased by the use of 
rejection therapies given for episodes of acute rejection particularly 
OKT3 (65), this factor did not influence the occurrence of skin cancer 
in the study. Furthermore, no association was found between the 
occurrence of skin cancers and the other individual 
immunosuppressant drugs. No relation was found between the 
occurrence of either warts, keratoses and skin cancers and the 
number of episodes of rejection that needed treatment.
The study had clinical and statistical limitations. Since the study 
mode was by means of questionnaires and few interviews and 
examinations and not always by detailed interviews and 
examinations, precise details could have been missed which is less 
likely with patient interaction. Dates of diagnosis of skin 
complications were not present so only crude point estimates could be 
done for statistical data analysis. The exact numbers of skin cancers 
diagnosed for each patient was not known because some patients, 
particularly ones who had greater number of skin cancers, did not 
remember the exact number. Measures of immunosuppression were 
crude and more detailed studies may be needed to make it more 
sensitive. Given more time, all patients would be questioned directly
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and examined, but this was not possible due to time constraints of the 
study.
Inadequate time was an important constraint in the present study. All 
the samples obtained could not be analysed.
Future research would focus on designing primers which amplify a 
smaller basepair region to determine HPV types in the degenerate 
DNA in archival tissue. We would preferentially like to collect fresh 
tissue for analysis to increase the chances of HPV detection. Further 
work on normal skin and hair samples would be useful to determine 
the passive or active nature of HPV. Another aspect for future 
research is the immunologic aspects of infection with human 
papillomaviruses and thus development of a vaccine which could lead 
to regression of the lesions already present. Antisense olinucleotides 
are also being evaluated. The goal of these immunomodulatory agents 
is not just to treat the cancer but to reduce subclinical and latent virus 
so that recurrences can be avoided.
Prevention strategies for these complications involve pre-transplant 
screening of patients, advice regarding avoidance of sun exposure to 
patients immediately post transplant and retinoid therapy which is 
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QUESTIONNAIRE FOR MALE TRANSPLANT RECIPIENTS
Please answer all questions and then return the questionnaire.
Please delete or circle the choices in italics, e.g. Yes/No or Yes/No
Name.......................... ,................... Today’s Date........
No.......................................... ........
DOB................................... ............  Date of Transplant.
Transplant: Heart / Heart ±Lung / Lung
Warts
1. Do you have warts? Yes / No
2. If yes, where? Face / Hands / Feet t Arms t Legs / Genital area
Other site (please specify).....................................................................
3. Were the warts present before the transplant? Yes /No
4. If so, for approximately how long?..............................................................................
5. Have you ever had any treatment for the warts? Yes /No
6. If so, what?........ ..........................................................................................................
6. Did it work? Yes / No
7. Did you have warts when you were younger / as a child? Yes / No 
Keratoses
8. Do you have any keratoses (rough, scaly spots) due to sun damage? Yes /No
9. If so, where? Face / Hands / Feet / Arms / Legs
Other site (please specify).....................................................................
Skin Cancer
10. Have you ever had a definite skin cancer? Yes /No
11. If so, where? Face / Hands / Feel / Arms / Legs / Genital area
Other site (please specify)................................... .................. ....... .
12. How was it treated?............................................... ......................................- ...............
You and the sun
13. What is your occupation?..................................... .......................................................
14. Have you ever worked regularly out of doors? Yes lNo
15. If so, what was the work and for how long did you do it?............................................
16. Have you ever lived or worked abroad? Yes /No
17. If so, where and for how long.............................................................................. ........
18. Do/ did you like to spend time sitting / lying in the sun? , Yes / No
19. If so, do /did you do this mainly at home / on holidays abroad?
20. Do you use a sun protection cream for your skin? Yes / No
21. If so, what do you use?.................................................................................................
22. Do you use this: Regularly / Occasionally
23. In the sun, do you: Burn / Tan after a little burning / Tan but rarely burn
24. What is your natural hair colour? Black / Brown / Blond / Sandy / Redhead
Your family
25. Do your relatives bum in the sun? Yes /.No
26. If so, please give details.............................................................................. .................
27. Have any of your relatives had a skin cancer? Yes t No
28 If so, please give details................................................................................................
29. Do any of you close relations have warts? Yes t No
30. If so, please give details................... ............................................................................
Skin
3 L Do you have any other skin trouble? Yes t No
If so, please give details...............................................................................................
